Literature DB >> 14678266

Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50.

F Driessler1, K Venstrom, R Sabat, K Asadullah, A J Schottelius.   

Abstract

Nuclear factor kappa B (NF-kappaB) is a transcription factor pivotal for the development of inflammation. A dysregulation of NF-kappaB has been shown to play an important role in many chronic inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease and psoriasis. Although classical NF-kappaB, a heterodimer composed of the p50 and p65 subunits, has been well studied, little is known about gene regulation by other hetero- and homodimeric forms of NF-kappaB. While p65 possesses a transactivation domain, p50 does not. Indeed, p50/p50 homodimers have been shown to inhibit transcriptional activity. We have recently shown that Interleukin-10 exerts its anti-inflammatory activity in part through the inhibition of NF-kappaB by blocking IkappaB kinase activity and by inhibiting NF-kappaB already found in the nucleus. Since the inhibition of nuclear NF-kappaB could not be explained by an increase of nuclear IkappaB, we sought to further investigate the mechanisms involved in the inhibition of NF-kappaB by IL-10. We show here that IL-10 selectively induced nuclear translocation and DNA-binding of p50/p50 homodimers in human monocytic cells. TNF-alpha treatment led to a strong translocation of p65 and p50, whereas pretreatment with IL-10 followed by TNF-alpha blocked p65 translocation but did not alter the strong translocation of p50. Furthermore, macrophages of p105/p50-deficient mice exhibited a significantly decreased constitutive production of MIP-2alpha and IL-6 in comparison to wild type controls. Surprisingly, IL-10 inhibited high constitutive levels of these cytokines in wt macrophages but not in p105/p50 deficient cells. Our findings suggest that the selective induction of nuclear translocation and DNA-binding of the repressive p50/p50 homodimer is an important anti-inflammatory mechanism utilized by IL-10 to repress inflammatory gene transcription.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14678266      PMCID: PMC1808913          DOI: 10.1111/j.1365-2249.2004.02342.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  45 in total

1.  IL-10 inhibits nuclear factor-kappa B/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes.

Authors:  M F Romano; A Lamberti; A Petrella; R Bisogni; P F Tassone; S Formisano; S Venuta; M C Turco
Journal:  J Immunol       Date:  1996-03-15       Impact factor: 5.422

Review 2.  The NF-kappa B and I kappa B proteins: new discoveries and insights.

Authors:  A S Baldwin
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

3.  Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers.

Authors:  H H Herfarth; S P Mohanty; H C Rath; S Tonkonogy; R B Sartor
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

4.  Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF-kappa B) which are involved in IL-6 regulation.

Authors:  W H Dokter; S B Koopmans; E Vellenga
Journal:  Leukemia       Date:  1996-08       Impact factor: 11.528

Review 5.  Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6.

Authors:  W Vanden Berghe; L Vermeulen; G De Wilde; K De Bosscher; E Boone; G Haegeman
Journal:  Biochem Pharmacol       Date:  2000-10-15       Impact factor: 5.858

6.  p50 (NF-kappa B1) is upregulated in LPS tolerant P388D1 murine macrophages.

Authors:  H W Ziegler-Heitbrock; I Petersmann; M Frankenberger
Journal:  Immunobiology       Date:  1997-12       Impact factor: 3.144

7.  Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse.

Authors:  K J Pennline; E Roque-Gaffney; M Monahan
Journal:  Clin Immunol Immunopathol       Date:  1994-05

8.  Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group.

Authors:  S J van Deventer; C O Elson; R N Fedorak
Journal:  Gastroenterology       Date:  1997-08       Impact factor: 22.682

9.  Interleukin-10 inhibition of the progression of established collagen-induced arthritis.

Authors:  M Walmsley; P D Katsikis; E Abney; S Parry; R O Williams; R N Maini; M Feldmann
Journal:  Arthritis Rheum       Date:  1996-03

10.  Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta.

Authors:  F Randow; U Syrbe; C Meisel; D Krausch; H Zuckermann; C Platzer; H D Volk
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  84 in total

1.  Interleukin-10 mediated autoregulation of murine B-1 B-cells and its role in Borrelia hermsii infection.

Authors:  Vishal Sindhava; Michael E Woodman; Brian Stevenson; Subbarao Bondada
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

Review 2.  IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy.

Authors:  Jun-Li Luo; Hideaki Kamata; Michael Karin
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

3.  X-linked Dystonia-Parkinsonism patient cells exhibit altered signaling via nuclear factor-kappa B.

Authors:  Christine A Vaine; David Shin; Christina Liu; William T Hendriks; Jyotsna Dhakal; Kyle Shin; Nutan Sharma; D Cristopher Bragg
Journal:  Neurobiol Dis       Date:  2016-12-22       Impact factor: 5.996

4.  Interleukin-10 plays a key role in the modulation of neutrophils recruitment and lung inflammation during infection by Streptococcus pneumoniae.

Authors:  Hernán F Peñaloza; Pamela A Nieto; Natalia Muñoz-Durango; Francisco J Salazar-Echegarai; Javiera Torres; María J Parga; Manuel Alvarez-Lobos; Claudia A Riedel; Alexis M Kalergis; Susan M Bueno
Journal:  Immunology       Date:  2015-09       Impact factor: 7.397

5.  Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6-dependent pathway.

Authors:  Sunil K Manna; Govindarajan T Ramesh
Journal:  J Biol Chem       Date:  2004-12-09       Impact factor: 5.157

6.  Risk association between the NF-κB1 -94ins/delATTG promoter polymorphism and inflammatory bowel diseases: a meta-analysis.

Authors:  Meilan Liang; Xinyu Xu; Yaoyao Gong; Yurong Tang; Lin Lin
Journal:  Dig Dis Sci       Date:  2012-07-25       Impact factor: 3.199

7.  Attenuated and lethal variants of Pichindé virus induce differential patterns of NF-kappaB activation suggesting a potential target for novel therapeutics.

Authors:  Gavin C Bowick; Susan M Fennewald; Lihong Zhang; Xianbin Yang; Judith F Aronson; Robert E Shope; Bruce A Luxon; David G Gorenstein; Norbert K Herzog
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

8.  Human IL10 gene repression by Rev-erbα ameliorates Mycobacterium tuberculosis clearance.

Authors:  Vemika Chandra; Sahil Mahajan; Ankita Saini; Hedwin K Dkhar; Ravikanth Nanduri; Ella B Raj; Ashwani Kumar; Pawan Gupta
Journal:  J Biol Chem       Date:  2013-02-28       Impact factor: 5.157

9.  Bordetella evades the host immune system by inducing IL-10 through a type III effector, BopN.

Authors:  Kanna Nagamatsu; Asaomi Kuwae; Tadashi Konaka; Shigenori Nagai; Sei Yoshida; Masahiro Eguchi; Mineo Watanabe; Hitomi Mimuro; Shigeo Koyasu; Akio Abe
Journal:  J Exp Med       Date:  2009-12-14       Impact factor: 14.307

Review 10.  Biological targets for therapeutic interventions in COPD: clinical potential.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Luca Gallelli; Teresa Renda; Mario Caputi; Rosario Maselli; Serafino A Marsico
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.